555 related articles for article (PubMed ID: 9416838)
61. The relationship between TP53 mutations and overexpression of p53 and prognosis in malignant gliomas of childhood.
Pollack IF; Hamilton RL; Finkelstein SD; Campbell JW; Martinez AJ; Sherwin RN; Bozik ME; Gollin SM
Cancer Res; 1997 Jan; 57(2):304-9. PubMed ID: 9000573
[TBL] [Abstract][Full Text] [Related]
62. p53 mutations in non-small cell lung cancer in Japan: association between mutations and smoking.
Suzuki H; Takahashi T; Kuroishi T; Suyama M; Ariyoshi Y; Takahashi T; Ueda R
Cancer Res; 1992 Feb; 52(3):734-6. PubMed ID: 1310070
[TBL] [Abstract][Full Text] [Related]
63. FGFR3 and Tp53 mutations in T1G3 transitional bladder carcinomas: independent distribution and lack of association with prognosis.
Hernández S; López-Knowles E; Lloreta J; Kogevinas M; Jaramillo R; Amorós A; Tardón A; García-Closas R; Serra C; Carrato A; Malats N; Real FX
Clin Cancer Res; 2005 Aug; 11(15):5444-50. PubMed ID: 16061860
[TBL] [Abstract][Full Text] [Related]
64. Expression of candidate tumor suppressor gene ING2 is lost in non-small cell lung carcinoma.
Ythier D; Brambilla E; Binet R; Nissou D; Vesin A; de Fraipont F; Moro-Sibilot D; Lantuejoul S; Brambilla C; Gazzeri S; Pedeux R
Lung Cancer; 2010 Aug; 69(2):180-6. PubMed ID: 19962781
[TBL] [Abstract][Full Text] [Related]
65. [Correlation between RARbeta gene promoter methylation and P53 gene mutations in non-small cell lung cancer].
Tan C; Jin YT; Xu HY; Zhang CY; Zhang H; Zhang WM; Chen CM; Sun XY
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 2012 Apr; 29(2):131-6. PubMed ID: 22487818
[TBL] [Abstract][Full Text] [Related]
66. Alterations of P16 (MTS1) in node-positive non-small cell lung carcinomas.
Marchetti A; Buttitta F; Pellegrini S; Bertacca G; Chella A; Carnicelli V; Tognoni V; Filardo A; Angeletti CA; Bevilacqua G
J Pathol; 1997 Feb; 181(2):178-82. PubMed ID: 9120722
[TBL] [Abstract][Full Text] [Related]
67. Effect of CYP1A1 MSPI polymorphism on the relationship between TP53 mutation and CDKN2A hypermethylation in non-small cell lung cancer.
Tan C; Xu HY; Zhang CY; Zhang H; Chen CM; Zhang WM; Sun XY; Jin YT
Arch Med Res; 2011 Nov; 42(8):669-76. PubMed ID: 22154617
[TBL] [Abstract][Full Text] [Related]
68. Prognostic value of TP53 and K-ras-2 mutational analysis in stage III carcinoma of the colon.
Pricolo VE; Finkelstein SD; Wu TT; Keller G; Bakker A; Swalsky PA; Bland KI
Am J Surg; 1996 Jan; 171(1):41-6. PubMed ID: 8554149
[TBL] [Abstract][Full Text] [Related]
69. p53 mutations in esophageal tumors from a high incidence area of China in relation to patient diet and smoking history.
Bennett WP; von Brevern MC; Zhu SM; Bartsch H; Muehlbauer KR; Hollstein MC
Cancer Epidemiol Biomarkers Prev; 1997 Nov; 6(11):963-6. PubMed ID: 9367071
[TBL] [Abstract][Full Text] [Related]
70. An abundance of p53 null mutations in ovarian carcinoma.
Skilling JS; Sood A; Niemann T; Lager DJ; Buller RE
Oncogene; 1996 Jul; 13(1):117-23. PubMed ID: 8700537
[TBL] [Abstract][Full Text] [Related]
71. [Evaluation of the prognostic significance of P53 mutation in patients with non-small cell lung cancer].
Jassem E; Rosell R; Jassem J; Monzo M; Kobierska G; Badzio A; Roszkiewicz A; Skokowski J; Szulc A
Pneumonol Alergol Pol; 1998; 66(5-6):290-6. PubMed ID: 9857649
[TBL] [Abstract][Full Text] [Related]
72. p53 from basic research to clinical applications.
Tominaga O; Hamelin R; Remvikos Y; Salmon RJ; Thomas G
Crit Rev Oncog; 1992; 3(3):257-82. PubMed ID: 1616957
[TBL] [Abstract][Full Text] [Related]
73. Molecular analysis of the von Hippel-Lindau disease tumor suppressor gene in human lung cancer cell lines.
Sekido Y; Bader S; Latif F; Gnarra JR; Gazdar AF; Linehan WM; Zbar B; Lerman MI; Minna JD
Oncogene; 1994 Jun; 9(6):1599-604. PubMed ID: 8183553
[TBL] [Abstract][Full Text] [Related]
74. Prognostic value of specific KRAS mutations in lung adenocarcinomas.
Siegfried JM; Gillespie AT; Mera R; Casey TJ; Keohavong P; Testa JR; Hunt JD
Cancer Epidemiol Biomarkers Prev; 1997 Oct; 6(10):841-7. PubMed ID: 9332768
[TBL] [Abstract][Full Text] [Related]
75. Expression of p53 and prognosis in children with malignant gliomas.
Pollack IF; Finkelstein SD; Woods J; Burnham J; Holmes EJ; Hamilton RL; Yates AJ; Boyett JM; Finlay JL; Sposto R;
N Engl J Med; 2002 Feb; 346(6):420-7. PubMed ID: 11832530
[TBL] [Abstract][Full Text] [Related]
76. p53 mutations in lung cancer following radiation therapy for Hodgkin's disease.
De Benedetti VM; Travis LB; Welsh JA; van Leeuwen FE; Stovall M; Clarke EA; Boice JD; Bennett WP
Cancer Epidemiol Biomarkers Prev; 1996 Feb; 5(2):93-8. PubMed ID: 8850268
[TBL] [Abstract][Full Text] [Related]
77. [Significance of heterozygosity loss in the long arm of chromosome 5 (5q21) in small cell carcinoma of the lung].
Sánchez Céspedes M; López Cabrerizo MP; Moreno I; Ariza A; Monzó M; Rosell R
Med Clin (Barc); 1997 May; 109(1):1-5. PubMed ID: 9303970
[TBL] [Abstract][Full Text] [Related]
78. p53 mutations and occupational exposures in a surgical series of lung cancers.
Harty LC; Guinee DG; Travis WD; Bennett WP; Jett J; Colby TV; Tazelaar H; Trastek V; Pairolero P; Liotta LA; Harris CC; Caporaso NE
Cancer Epidemiol Biomarkers Prev; 1996 Dec; 5(12):997-1003. PubMed ID: 8959323
[TBL] [Abstract][Full Text] [Related]
79. [Genetic alteration of lung cancer as a prognostic marker and its therapeutic implications].
Mitsudomi T; Takahashi T
Gan To Kagaku Ryoho; 1997 Oct; 24 Suppl 3():345-52. PubMed ID: 9369906
[TBL] [Abstract][Full Text] [Related]
80. p53 mutations in head and neck cancer: new data and evaluation of mutational spectra.
Olshan AF; Weissler MC; Pei H; Conway K
Cancer Epidemiol Biomarkers Prev; 1997 Jul; 6(7):499-504. PubMed ID: 9232336
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
